Clinical Trials
5 trialsNCT03620201 2024-10-22
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04756505 2023-12-27
Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03579472 2022-10-31
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT03524170 2022-03-07
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04296942 2022-01-11
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated